The Canadian government has given the green light to a startup for the exportation of psychedelic substances to Australia for medicinal purposes. The health department has officially authorised Optimi Health Corp. to ship pills laden with psilocybin, an extract from magic mushrooms, and MDMA.
The growing demand transcends local magic mushrooms Ontario. Other countries are taking notes from Canada and beginning to investigate and approve the medical use of serotogenic compounds.
Securely buy psychedelics online in Canada and tap into your innate potential via trustworthy sources.
[toc]Main Points:
- Optimi Health, a Vancouver-based startup, has been awarded a drug establishment license to export magic mushroom pills to Australia.
- Australia allows licenced psychiatrists to use magic mushrooms in treating chronic depression.
- The treatment consists of three sessions, spaced out over five to eight weeks, with each session lasting around eight hours.
The Rise of Psilocybin Capsules in Canada
Optimi, a budding company in Vancouver, aims to use its certification to broaden the pharmaceutical market for psychedelic drugs and secure a lead in the early market.
Seven firms have exported psilocybin, MDMA, or both, but only for the purpose of clinical trials. An official from Canada’s health department could not confirm if these exports were for regular patient use and chose not to reveal the companies for security reasons.
This feat places Optimi among a unique group of international suppliers, with the current market favouring clinical over recreational use.
What Does the Pill Contain?
While the company has not disclosed the specific mushroom used in the pill, it does employ a variety of strains, including Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, for the cultivation, testing, and extraction of its psychedelic mushrooms. This quaint town, home to approximately 3,000 residents, is situated three hours to the east of Vancouver.
Australia’s Relationship with Psychedelic Mushrooms
It’s estimated that one in five Australians, aged between 16 and 85, may experience mental illness. Post-traumatic stress disorder (PTSD) is projected to affect 11% of Australians at some point, while anxiety disorders are common among 17% of the populace.
There is a vast array of mental health treatment methods, but their effectiveness varies from person to person. For those who don’t respond to certain treatments, finding a beneficial approach can be a daunting task, thereby heightening their susceptibility.
Understanding the Process
Australia has been at the forefront of using psilocybin, allowing certified psychiatrists to employ this regulated substance in treating PTSD and depression that are resistant to traditional treatments.
In an unexpected turn of events in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and mushrooms for therapeutic purposes. The TGA declared these substances safe for use in a medically supervised setting for patients battling severe mental disorders.
This shift has been revolutionary for numerous mental health professionals and researchers. The use of these substances will be strictly monitored; it’s not as simple as ingesting a pill and departing.
The treatment protocol typically includes three sessions spread over a period of five to eight weeks. Each session lasts approximately eight hours, with the therapist accompanying the patient the entire time.
Canada’s Role in Psilocybin Research
Canada has come into prominence as a vital center for psilocybin research, greatly enriching our understanding of this substance. Health Canada, in collaboration with several institutions, is spearheading the investigation of the therapeutic potential of psilocybin in treating a variety of mental health conditions.
Research institutions are no longer obligated to label these substances as illegal or rely on unlicensed dispensaries or mushroom shops. The government now permits certain institutions to cultivate mushrooms for research purposes.
The newfound availability of substances previously deemed harmful empowers researchers to expand their understanding of their potential benefits to a wide range of individuals.
A Cyclical Trend
In the 1950s, the potential of the field to tackle mental health issues and substance abuse, inclusive of alcoholism, was first identified. This early research was spearheaded by English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer at the Weyburn The Saskatchewan Mental Hospital. Under the leadership of then-Premier Tommy Douglas, the hospital saw significant progress due to the autonomy granted to the medical community to investigate their theories.
The research journey of Dr. Osmond and Dr. Hoffer included the exploration of LSD, mescaline, and peyote as possible alternatives to harsh procedures such as electroshock and lobotomy. The research took an unexpected turn when the pair suggested that doctors, nurses, and auxiliary staff should also experiment with these substances.
Research by Canadian Institutes of Health
The Institute of Neurosciences, Mental Health and Addiction, under the Canadian Institutes of Health Research, is funding three clinical trials. These trials are to investigate the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Principal Investigator | Project Budget |
| A randomized controlled trial | Psychological distress in terminal-stage cancer patients | University of Toronto | Sarah Hales | $928,643 |
| Psilocybin psychotherapy mechanisms for treating alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial contrasting single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
The Canadian Drugs and Substances Strategy (CDSS), initiated by the Canadian Government, has enabled funding for this research. This will contribute to a broader understanding of the benefits of controlled substances.
Further Psychedelic Research
In Vancouver, psychiatrists have begun a phase III clinical trial of MDMA, commonly known as ecstasy, for treating post-traumatic stress disorder (PTSD). The treatment involves three eight-hour sessions with MDMA, scheduled a month apart, and nine 90-minute sessions without the drug. This trial is considered historically significant as it is the first clinical evaluation of an illegal
It has been more than four decades since a psychedelic substance was investigated.
Exploring Psilocybin
Psilocybin, a psychedelic compound that naturally occurs in certain types of mushrooms, transforms into psilocin when ingested. This psilocin activates the serotonin 5-HT2a receptors in the cortical pyramidal cells of the brain, which are primarily responsible for processing information.
Currently, researchers are examining the substance’s potential to assist with depression, anxiety, addiction, and end-of-life distress by promoting introspection and spiritual enlightenment.
Why is it Potentially Effective in Treating Depression, PTSD, and Other Conditions?
The active ingredient interacts with several brain areas, making it potentially helpful in treating a variety of mental health conditions. This therapy has already been used in patients in Canada and Australia with promising results, and side effects like temporary anxiety or increased blood pressure, although present, have been minimal.
Impact on Neurobiology
- Activation of Serotonin Receptors: The compound acts as a partial agonist at serotonin receptors, particularly the 5-HT2A subtype, playing a key role in regulating mood and processing emotions.
- Modulation of Default Mode Network (DMN): The substance reduces DMN activity, which promotes introspection, enhances emotional flexibility, and diminishes rigid thinking patterns.
- Stimulation of Prefrontal and Limbic Regions: The antidepressant effects of this compound derive from its influence on the prefrontal and limbic regions of the brain, including the amygdala. Depression often results in a weaker response to emotional stimuli. However, this compound enhances positive emotional responses in the right amygdala and either reduces or normalizes responses to negative or neutral emotional stimuli.
Effects on Psychology and Emotions:
- Generation of Positive Mood States: The substance induces feelings of euphoria, interconnectedness, and emotional openness during and after the experience.
- Enhanced Emotional Processing: The psychedelic experience may facilitate individuals to confront and process deeply embedded emotions, traumatic memories, or existential concerns in a supportive setting.
- Existential and Spiritual Insights: Studies conducted at Johns Hopkins University and Imperial College London asserts that it can precipitate enduring positive transformations, incorporating enhanced well-being, amplified life satisfaction, and spiritual growth.
What Can You Discover at Your Local Magic Mushroom Outlets?
Interested in how the substance might affect your mental health? You can peruse magic mushroom stores to find a product that suits your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Improves mood, inspires creative thought, and amplifies productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Boosts wellness and enhances overall quality of life |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Encourages clarity, creativity, and focus. Contains a powerful mix of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy benefits |
International Acceptance of Psilocybin
Canada isn’t the only nation supporting the utilization of magic mushrooms for mental health conditions. Countries like Australia are also embracing these hallucinogens to manage disorders such as depression and PTSD. They are procuring top-quality psychedelic capsules from trustworthy sources. Under suitable supervision, patients can significantly improve their life quality. Shrooms Online Canada, a magic mushroom supplier, offers a variety of products, from tablets to LSD edibles.
Frequently Asked Questions
How do psilocybin and MDMA compare?
Both psilocybin and MDMA have therapeutic potential by promoting mental well-being. Psilocybin interacts with serotonin 2A receptors and is beneficial for treating depression and addiction.
Conversely, MDMA encourages empathy and is effective in PTSD therapy. It demonstrates potential in improving emotional processing and
Even though it’s classified as a controlled substance, it can still lead to beneficial therapeutic results.
Is this treatment option accessible to all Australians?
Not all Australians can access this treatment. Before using the substance, an individual must undergo an assessment to verify their suitability. This assessment takes into account various factors such as pre-existing heart conditions and a history of psychosis. Only patients who have not responded to conventional treatments for conditions like depression, anxiety, and PTSD can access this treatment.
What impact will Canada’s export of mushrooms have?
With its mushroom export, Canada is aiming to become a leading player in the psychedelics market, mirroring its approach to cannabis. Such a move could lead to an increase in companies producing high-quality products. This could result in Canada becoming a global leader in the hallucinogen market, strengthening its economy, and enabling other countries to gain access to these treatments. It could also discourage countries from obtaining hallucinogens from illegal dispensaries or suppliers, thus guaranteeing safety.
Recommended Articles:
